AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00567333 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Multidisciplinary, integrative care
Description: A combination of therapies which may include acupuncture/Oriental medicine, chiropractic, cognitive behavioral therapy, exercise therapy, medicine, self-care information, and massage therapy.
Study NCT04302805 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Privigen
Description: Patients randomized to PE/rATG/IVIG group will receive IVIG 0.5g/kg infusions, on 1st, 3rd and 5th postoperative day.
Study NCT04302805 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Thymoglobulin
Description: All patients will receive 1.5 mg/kg intraoperatively and 1 mg/kg when possible daily within first week up to cumulative dose 5-7 mg/kg.
Study NCT04302805 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thymoglobulin
Description: All patients will receive 1.5 mg/kg intraoperatively and 1 mg/kg when possible daily within first week up to cumulative dose 5-7 mg/kg.
Study NCT04302805 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Plasma Exchange
Description: All patient will undergo Plasma Exchange before transplantation.
Study NCT04302805 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plasma Exchange
Description: All patient will undergo Plasma Exchange before transplantation.
Study NCT00676325 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NAZCA TC™ POP REPAIR SYSTEM ,promedon® , argentina.
Description: Women 50 years and older with greater anterior vaginal prolapse,whit stress incontinence or not, requiring surgical correction .
Study NCT00676325 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical treatment for anterior vaginal wall prolapse
Description: Women 50 years and older with greater anterior vaginal prolapse,whit stress incontinence or not requiring surgical correction were eligible for participation.
Study NCT01882179 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mineralocorticoid receptor antagonist potassium-canrenoate
Study NCT01882179 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00976794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lithium plus carbamazepine
Description: Lithium: Starting at 600 mg daily, dose weekly adjusted according to blood serum level (0,6 -1,2mEq/l), efficacy and tolerability.~Carbamazepine : Starting at 200mg daily and getting 600 mg daily at the end of the first week. Dose weekly adjusted according to blood serum level (8 and 12µg/ml), efficacy and tolerability
Study NCT01895023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: The dexmedetomidine group received intranasal dexmedetomidine 2mcg/kg premedication 45 min before induction of anaesthesia.
Study NCT00976794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lithium plus valproate
Description: Lithium: Starting at 600 mg daily, dose weekly adjusted according to blood serum level (0,6 -1,2mEq/l), efficacy and tolerability.~Valproic acid: Starting at 500mg daily, dose weekly adjusted according to blood serum level (50 and 125µg/ml), efficacy and tolerability.
Study NCT01895023 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: The midazolam group oral midazolam 0.5 mg/kg 30 min before induction of anaesthesia.
Study NCT01895023 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: The Placebo group received intranasal saline premedication 45 min and oral saline 30 min before induction of anaesthesia
Study NCT03227224 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive 2 placebo capsules matching JNJ-42847922 once daily orally from Day 1 to Day 41 (Week 6).
Study NCT03227224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922
Description: Participants will receive 2 capsules of JNJ-42847922 once daily orally from Day 1 to Day 41 (Week 6).
Study NCT03894241 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity
Description: Participants will assist to the three different sessions at the same weekday (e.g., Monday) and at the same daytime to avoid differences in preceding school activities or circadian rhythms. Participants will undergo a Sedentary condition (SC), sitting and watching a documentary on TV as has been used previously, and two different PA protocols consisting in Moderate-Intensity Continuous Training (MICT), i.e., continuous outdoor walking, and Cooperative High-Intensity Interval Training (C-HIIT), composed of a circuit training with a partner (physical education teacher)
Study NCT02919826 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted Dialectical Behaviour Therapy
Description: 12 weekly sessions of DBT group therapy
Study NCT01974908 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fibrillatory Factor calculation (FF)
Description: During sinus rhythm these patients will undergo a simple pacing protocol to allow us to calculate FF, which is an area we would predict is mod likely to be the origin of their VT.
Study NCT04259138 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Treatment Algorithm A
Description: Participants who are not on UC treatment at screening (or who have only used topical therapy) will require standard first-line therapy. Either oral 5-ASA and/or immunosuppressive (azathioprine, 6-mercaptopurine, or methotrexate), with optional oral corticosteroid up to a maximum of 30 mg or prednisone or equivalent, will be initiated.
Study NCT04259138 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Treatment Algorithm B
Description: Participants who are taking oral 5-ASA, immunosuppressive (azathioprine, 6-mercaptopurine, methotrexate), and/or oral corticosteroid at screening will follow the treatment algorithm.~Participants will change to intravenous vedolizumab therapy.~Participants will be assessed to determine it remission target is achieved at weeks 16, 32 and 48. If the participant has achieved their treatment target, they will continue that line of therapy. If the participant has not achieved their treatment target, treatment and/or dose escalation will be administered according to the algorithm.
Study NCT00098553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Study NCT03109795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine Pill
Description: sympathetic nerve activity blockade
Study NCT03109795 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: Blood pressure-lowering control condition
Study NCT04004819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: A lower dosage of rituximab for HTLV-1-associated myelopathy
Study NCT01296191 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: One drop 4 times daily for 3 days and one drop the day of sample collection
Study NCT01296191 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: besifloxacin
Description: One drop 4 times daily for 3 days and one drop on day of sample collection
Study NCT03844269 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AKL-T01
Description: AKL-T01 digital treatment is a state-of-the-art mobile video game-like platform, which deploys modern videogame graphics, engaging reward loops, and real-time adaptive mechanics to dynamically personalize difficulty based on the user's ability. AKL-T01 multitasking treatment employs perceptual discrimination attention/memory task as well as a continuous motor driving task. Performance on these tasks are assessed in isolation and when performed together to calculate a performance index for each individual user. A personalized multitask treatment regimen is automatically configured and delivered to the user and is optimized adaptively to increase multitask performance. As players proceed through the treatment periodic recalibration occurs to maintain an optimal difficulty level.
Study NCT03823196 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum900
Description: Sinetrol® Xpur is a blend of polyphenol-rich extracts from grapefruit, guarana seed, sweet orange and blood orange. Daily dosage is 900 mg for 16 weeks
Study NCT03823196 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum1800
Description: Sinetrol® Xpur is a blend of polyphenol-rich extracts from grapefruit, guarana seed, sweet orange and blood orange. Daily dosage is 1800 mg for 16 weeks
Study NCT00413257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nefopam
Description: 0,3mg/kg IV bolus preoperative and 65 µg/kg/h during H48 postoperative
Study NCT00413257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: néfopam
Description: bolus Néfopam (0,3mg/kg) during 10 min at the end of surgery and 65 µg/kg/h during postoperative H48
Study NCT00413257 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: bolus NaCl during 10 min at the end of surgery and during postoperative H48
Study NCT04370418 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: short course chemo-radiation with 5-fluorouracil
Description: neo-adjuvant short course chemo-radiation in locally advanced rectal cancer patients followed by delayed surgery
Study NCT03495713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 3 mg/kg will be administered on day 1 (pre-response assessment week 0) and on day 1 and continued per standard of care and institutional practices. A
Study NCT03663504 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Preparation
Description: No preparation before surgery
Study NCT03663504 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neomycin and Flagyl
Description: Oral antibiotic (Neomycin and Flagyl) taken the day before the surgery
Study NCT03737240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDegLira
Description: Participants in this study arm will discontinue all other diabetes medications, except for metformin which will be continued at prescribed dose (unless contraindicated). IDegLira will be given once daily, at the same time of the day with or without food for 26 weeks. IDegLira will be titrated until the maximum dose is reached, up to the target fasting blood glucose of 70 to 100 milligrams per deciliter (mg/dL).
Study NCT03737240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Degludec (U-100)
Description: Participants in the basal-bolus insulin study arm will discontinue all other diabetes medications, except for metformin which will be continued at the prescribed dose (unless contraindicated). Insulin Degludec (U-100) will be given once daily at the same time for 26 weeks. The dose will be titrated up to the fasting blood glucose target of 70 to 100 mg/dL, with no maximum dose.
Study NCT03737240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Aspart
Description: Participants in the basal-bolus insulin study arm will discontinue all other diabetes medications, except for metformin which will be continued at the prescribed dose (unless contraindicated). Insulin aspart will be taken before meals with a titration schedule and dose adjustment protocol to target pre-meal blood glucose level of 70 to 100 mg/dL.
Study NCT02700191 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: uCor
Study NCT03873337 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Persistence Targeted Smoking Cessation in SMI (PTSC-S)
Description: All participants will receive 8 weeks of persistence focused smoking cessation counseling delivered via telehealth
Study NCT03873337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: All participants will receive 10 weeks of nicotine patch
Study NCT00073814 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo MDI QID
Study NCT03304470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATx201 2% Cream
Description: Anhydrous Cream
Study NCT03304470 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ATx201 Cream Vehicle
Description: Anhydrous Cream
Study NCT00995670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% dextrose
Description: Glucose is infused to prevent the anesthetic preconditioning (sevoflurane) protection against subsequent ischemia/reperfusion injury.
Study NCT00995670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Vitamin C is intended to restore the impairment of the endothelium caused by the dextrose infusion.
Study NCT00995670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin will be ingested to determine the efficacy of a statin to modulate the forearm response to glucose.
Study NCT00995670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Sevoflurane will be given to attenuate or prevent the I/R injury during glucose.
Study NCT04697433 — intervention group
Intervention type: DEVICE
Intervention: Myotonometry
Description: The examiner should exert a slight pressure on the determined point to the necessary depth, which will be indicated by changing the color from red to green light on the device. The device has an automatically controlled preload (0.18 Newton (N)) that will be applied to the contact area by an automatic mechanical pulse, with a duration of 15 milliseconds (ms) and a constant force of 0.4 N , these oscillations will be registered by an accelerometer next to the measurement mechanism inside the device. For each evaluation, a series of 10 consecutive pulses (multiscan mode) will be used with an interval of one second between each pulse. In each shot, the tone, stiffness, elasticity, relaxation time and creep will be calculated.
Study NCT00293423 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSPPC-96
Description: 25 mcg
Study NCT00293423 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Surgical Resection
Description: Patients will undergo standard surgical resection of intracranial tumor
Study NCT03691753 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitaya Vena Cava Filter System
Description: After the implantation of Fitaya Vena Cava Filter, the filter can be withdrawn from the patient within the window period (60 days) by using the withdraw system in junction of the sheath.
Study NCT03691753 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aegisy Vena Cava Filter
Description: After the implantation of Aegisy Vena Cava Filter, the filter can be withdrawn from the patient within the window period (60 days) by using the withdraw system in junction of the sheath.
Study NCT03658993 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rifaximin 550 MG
Description: Oral Rifaximin 550 mg TID for 4 weeks.
Study NCT03658993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin 550 MG
Description: Oral Rifaximin 550 mg TID for 4 weeks.
Study NCT00835107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ziprasidone hydrochloride
Description: oral capsules, from 40-80 mg BID, for one month with the option to continue the medication after the study has been completed
Study NCT00835107 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo comparator, oral capsules, BID, for one month
Study NCT04015414 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: 191 patients will receive varenicline for 12 weeks and regular phone calls with brief counseling Tabex: 188 patients will receive cytisine for 25 days and regular phone calls with brief counseling
Study NCT04015414 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytisine
Description: 185 patients will receive cytisine for 25 days and regular phone calls with brief counseling
Study NCT03472274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500 mg every 4 weeks x 3 cycles
Study NCT03472274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab 75 mg every 4 weeks x 3 cycles
Study NCT03472274 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin-based neoadjuvant chemotherapy
Description: Regimen 1: 21-day treatment cycle x 3 cycles.~* Gemcitabine 1,000-1,200 mg/m2 intravenously on days 1 and 8 every 21 days.~* Cisplatin 70 mg/m2 intravenously on day 1 every 21 days. Regimen 2: ddMVAC 14-day treatment cycle x 4 doses.~* Methotrexate 30mg/m2 intravenously on day 1~* Vinblastine 3mg/m2 intravenously on day 2~* Doxorubicin 30mg/m2 intravenously on day 2~* Cisplatin 70mg/m2 intravenously on day 2 Granulocyte colony-stimulating factor (G-CSF) for 7 consecutive days (days 4 through 10).~Regimen 3: 21-day treatment cycle x 3 cycle~* Gemcitabine 1,000 mg/m2 intravenously on day 1 and 8~* Paclitaxel 80 mg/m2 intravenously on day 1 and 8~* Cisplatin 70mg/m2 intravenously on day 1
Study NCT02089620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Yasmin
Description: will be used every 21 days for three months by the patient
Study NCT02089620 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calver
Description: Calver will be given daily for 3 months
Study NCT02089620 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 1
Description: Patients will receive a daily placebo similar in size and structure to calvar.
Study NCT02089620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo 1
Description: Patients will receive a daily placebo similar in size and structure to calvar.
Study NCT02089620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo 2
Description: Women will receive an oral placebo similar to COC for 21 days starting from the 3rd day of menstruation
Study NCT02089620 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 2
Description: Women will receive an oral placebo similar to COC for 21 days starting from the 3rd day of menstruation
Study NCT04158986 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-driven post-discharge intervention
Description: Home visits based on the concepts of Family Nursing:~The participants will receive three home visits by a nurse who is trained in the Family Nursing principles during the first 12 weeks after discharge.~The home visits will comprise of:~* Filling in the Chronic Liver Disease Questionnaire.~* Therapeutic conversations including drawing and review of genogram and eco-map.~* Information about- and help to initiate contact to relevant municipal offers.~* Evidence-based information based on the patient's current problems or symptoms, base-line knowledge and receptiveness.~Follow-up telephone calls:~• After the first 12 weeks participants will be followed-up by telephone monthly during the following 12 weeks.~Pamphlet:~• All participants will receive a pamphlet with brief information regarding preventive measures and early signs of decompensation as well as relevant contact details. The pamphlet will be handed out before discharge
Study NCT04597619 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novel Nonopioid Pathway
Description: The novel nonopioid pathway consists of preoperative counseling, postoperative standardized orders and standard of care adjunctive and analgesic medications, specialized discharge instructions and written patient instructions regarding medications and activity.
Study NCT03448861 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polso Wearebale watch
Description: The objective of the Polso™ feasibility study is to demonstrate the suitability of Polso™ as a data acquisition and processing platform by comparison with the conventional British version of EWS (UK-NEWS) on aggregate and on each individual parameter score. Although in a full NEWS system, the frequency of testing is determined by the score itself, this aspect will not be evaluated, in the event that a divergence of scores would complicate clinical evaluation and correspondence of readings. In addition, good clinical practice calls for patient care to be fully motivated by the NEWS currently in use, as opposed to the experimental Polso™. Therefore, this compromise will be made, which will still permits system evaluation.
Study NCT03110419 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Exercise
Description: The intervention program will follow the recommendations of the American College of Sports Medicine (ACSM, 2009), including aerobic, muscle strength, flexibility and balance exercise. The duration of the intervention will be 16 weeks with sessions 60 min performed in three alternate days.
Study NCT02947022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium DTPA
Description: On Day 1, 2.5 mL of Ca-DTPA (1 g/5 mL) will be administered over a period of 1 minute. A solution of normal saline will then be administered at a rate of 300 mL/hr over 30 minutes. Patients will be seated with hands lowered to their sides to allow the chelator to dwell slightly in the soft tissues of the hands and feet. Patients will then be moved to a supine position and the infusion rate increased to 750 mL/hr over the next 60 minutes. At 90 minutes the remaining 2.5 mL of Ca-DTPA will administered IV over a period of 1 minute, and the normal saline will continue for the remaining 9 minutes. The IV line will then be removed. Patients will be instructed to drink plenty of fluids that evening.~The same treatment therapy will consist of 3 time-points, approximately 1 month apart.